为评估对传统FSH诱导排卵方案耐药的多囊卵巢综合征(PCOS)患者加用生长抑素类似物能否改善卵巢的反应,并减少卵巢过度刺激综合征(OHSS)的危险,设计一项前瞻性自身对比干预性研究。选择6例PCOS无排卵不育的患者,均为雄激素升高和糖耐量异常的高雄激素、高胰岛素血症和单独应用传统方案FSH诱导排卵3个周期失败者。年龄22～37岁,平均体质指数(BMI)22.1kg/m~2。采用长效生长抑素类似物(Sandostatin)联合FSH治 To evaluate whether the addition of somatostatin analogues in women with polycystic ovary syndrome (PCOS) resistant to conventional FSH-induced ovulation induction can improve ovarian response and reduce the risk of ovarian hyperstimulation syndrome (OHSS), a Prospective self-contrast intervention study. Six cases of PCOS with anovulatory infertility were selected, all of which were androgen and hyperinsulinemia with hyperglycemia and hyperinsulinemia and three cycles of ovulation induction by FSH alone. Aged 22-37 years old, the average body mass index (BMI) 22.1kg / m ~ 2. The use of long-acting somatostatin analogues (Sandostatin) combined with FSH treatment